Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Cost of Revenue (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Cost of Revenue for 12 consecutive years, with $5.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Cost of Revenue rose 5.1% to $5.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $20.9 million, a 9.07% decrease, with the full-year FY2025 number at $20.6 million, down 6.94% from a year prior.
  • Cost of Revenue was $5.5 million for Q4 2025 at Aytu Biopharma, up from $4.7 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $12.2 million in Q2 2021 to a low of $4.1 million in Q4 2023.
  • A 5-year average of $7.7 million and a median of $7.7 million in 2024 define the central range for Cost of Revenue.
  • Peak YoY movement for Cost of Revenue: skyrocketed 115.24% in 2021, then crashed 60.75% in 2023.
  • Aytu Biopharma's Cost of Revenue stood at $9.7 million in 2021, then increased by 9.32% to $10.6 million in 2022, then plummeted by 60.75% to $4.1 million in 2023, then increased by 27.19% to $5.3 million in 2024, then rose by 5.1% to $5.5 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Cost of Revenue are $5.5 million (Q4 2025), $4.7 million (Q3 2025), and $5.5 million (Q2 2025).